The nestin + perivascular bone marrow (BM) stem cell niche (N + SCN) may be involved in GvHD. To investigate whether acute GvHD (aGvHD) reduces the number of N + SCN, we examined patients with AML who had undergone allogeneic hematopoietic stem cell transplantation. In the test cohort (n = 8), the number of N + SCN per mm 2 in BM biopsies was significantly reduced in aGvHD patients at the time of aGvHD compared with patients who did not have aGvHD (1.2 ± 0.78 versus 2.6 ± 0.93, P = 0.04). In the validation cohort (n = 40), the number of N + SCN was reduced (1.9 ± 0.99 versus 2.6 ± 0.90 N + SCN/mm 2 , P = 0.05) in aGvHD patients. Receiver operating curves suggested that the cutoff score that best discriminated between patients with and without aGvHD was 2.29 N + SCN/mm 2 . Applying this cutoff score, 9/11 patients with clinically relevant aGvHD (⩾ grade 2) and 13/20 with any type of GvHD had decreased N + SCN numbers compared with only 10/29 patients without clinically relevant aGvHD (P = 0.007) and 6/20 patients without any type of GvHD (P = 0.028). In patients tracked over time, N + SCN density returned to normal after aGvHD resolved or remained stable in patients who did not have aGvHD. Our results show a decrease in the number of N + SCN in aGvHD.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for patients with hematological malignancies.
1,2
The success rate of HSCT is severely limited by acute GvHD (aGvHD), which is mediated by host-reactive, donor-derived T cells. 3 The primary target tissues of these T cells are host epithelia in the skin, liver and intestine. 3, 4 There is increasing evidence that the bone marrow (BM) stem cell niche and endothelial cells are also targets of GvHD. [5] [6] [7] [8] [9] [10] Moreover, hematopoietic dysfunction, especially thrombocytopenia, is associated with GvHD. 5, 8 Marrow failure in such instances is thought to be due to disruption of the donor hematopoiesis by cytokines (especially interferon-γ and tumor necrosis factor-α) released during GvHD. Recent experimental evidence suggests that impairments of the host hematopoietic stem cell niche (HSCN) might be even more relevant. 5 Observations with regard to the increased host-derived intramedullar new vessel formation in GvHD provide additional evidence that perturbation of the host-derived stromal/niche components is involved in GvHD-related marrow failure. [11] [12] [13] Two types of BM niches have been identified in the recent years. The endosteal niche is located along the bony trabeculae and is composed of mainly osteoblasts. The perivascular niche is formed by sinusoidal vascular endothelial cells and perivascular cells. Both the endosteal and perivascular niches have important roles in regulating self-renewal capacity and maintaining stability of the HSC pool. In a MHC-haploidentical matched murine HSCT model, the perivascular niche was shown to be a target of aGvHD.
14 Tissue-resident nestin + multipotent mesenchymal stem cells seem to be involved in intramedullary vessel stabilization, and the nestin + perivascular compartment is thought to represent the perivascular HSCN. 15 Nestin is a class VI intermediate filament protein that is expressed during the early developmental stages of the central nervous system in dividing cells; it is also expressed in peripheral nervous system tissue, myogenic tissue and nonneuronal immature or progenitor cells. After cellular differentiation, nestin is downregulated and replaced by a tissue-specific intermediate filament, such as neurofilaments in neurons and desmin in muscles; nestin is therefore thought to be a neuronal stem cell marker. [16] [17] [18] [19] In adult organisms, nestin-expressing cells are restricted mainly to defined areas of regeneration, where they function as a cellular reserve capable of proliferation, differentiation and migration after reactivation. 19, 20 In the BM, the nestin + mesenchymal stem cells innervated by sympathetic nerve fibers regulate normal HSCs, and sympathetic innervation rescues nestin + mesenchymal stem cells from apoptosis. Thus this niche seems to be pharmacologically targetable. 21 Pro-inflammatory signaling by cytokines (also involved in aGvHD) has been shown to disrupt this niche in myeloproliferative neoplasms. 21 To investigate whether GvHD reduces the number (and thus impairs the function) of the nestin + HSCN, we examined a test cohort and a validation cohort of patients with AML who had undergone HSCT.
PATIENTS AND METHODS Patients
The study was performed according to the regulations of the local ethics committee (approval number EKNZ 2014-252). We hypothesized that numerical differences of nestin + niches exist between patients with clinically relevant GvHD and patients without GvHD and applied our hypothesis first in a test cohort (n = 8) and then confirmed our observations in a validation cohort (n = 40). The patient characteristics of the test cohort and the validation cohort are shown in Table 1 ; the test cohort was recruited from a previous study collective. 13 Our cohorts met the following inclusion criteria; all patients (1) had AML; (2) had undergone HSCT at our institution between 2004 and 2013; (3) had documented none, acute and/or chronic GvHD (at the time point reported at point 4) diagnosed and graded according to standard criteria; (4) had trephine BM biopsies available from before allo-HSCT and as of the onset of aGvHD (range 1-17 days before the onset of aGvHD) or (for patients who did not have GvHD) 1-4 months after allo-HSCT and after aGvHD resolved or (for patients who did not have GvHD) 6-12 months after allo-HSCT (one missing biopsy at the beginning of the last time point, not at the middle time point, was acceptable); and (5) had AML that was in CR pretransplant at aGvHD and after HSCT. AML was diagnosed according to the World Health Organization criteria. 22 Remission status was defined according to the guidelines of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in AML. 23 Acute and chronic GvHD were diagnosed based on clinical symptoms and/or skin, oral mucosa, liver or gut biopsies and were graded using consensus criteria for aGvHD and chronic GvHD. 24, 25 GvHD prophylaxis administered along with the myeloablative conditioning regimens was cyclosporine A and methotrexate as well as anti-T-cell globulins in the case of an unrelated donor. In patients with reduced-intensity conditioning (RIC), the GvHD prophylaxis consisted of cyclosporine A, methotrexate and anti-T-cell globulins in the case of an unrelated donor (if RIC was fludarabine/ busulfan) or cyclosporine A and mycophenolate mofetil (if RIC was fludarabine/2 Gy low-dose TBI). Corticosteroid treatment (methylprednisolone, intravenously, 2 mg/kg per day) was started immediately after diagnosis of ⩾ grade 2 aGvHD. Patients were maintained, concurrently with steroid treatment, on therapeutic levels of cyclosporine A in myeloablative conditioning or cyclosporine A/mycophenolate mofetil in RIC. Chimerism analysis of whole blood was conducted at each protocol follow-up examination after HSCT using a short tandem repeat analysis method (AmpFlSTR Profiler, Applied Biosystems, Foster City, CA, USA). Clinical, laboratory (peripheral blood counts) and follow-up data were obtained by reviewing the charts.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue samples were used throughout. Details of the applied antibodies are listed in Table 2 . For nestin/CD34 double stainings, the CD34 antibody was applied after labeling of nestin and visualized using an alternative Chromogenic Detection Kit (basic aminoethyl-carbazole from Ventana/Roche, Tuscon, AZ, USA). To study the endosteal niche in the BM samples, optical scoring was performed taking into account the number of nestin + perivascular niches (either single cells or clusters of up to three cells), the number of FOPX3 + cells and the presence of pro-collagen 1 + osteoblasts. On average, 7.2 mm 2 /case was evaluated, and the results were extrapolated to 1 mm 2 . Microvessel density (MVD) was assessed as reported elsewhere. 13 The investigators were blinded to the clinical data at the time of immunohistochemical analysis.
Statistical analysis
Statistical analyses, including distribution analysis and descriptive statistics, were performed with IBM SPSS Statistics 22.0. Comparisons were performed using the Kruskal-Wallis and Mann-Whitney U-tests. For correlation analysis, Fisher's exact test was applied. To assess changes in the HSCN over time, the R 2 application was used. Because differences in the numbers of nestin + niches were hypothesized to exist between patients with aGvHD and those without GvHD, we postulated clinically relevant GvHD to be the defining set variable in a receiver operating characteristic (ROC) curve model plotting nestin + stem cell niche numbers' sensitivity versus 1 − specificity to discriminate between patients with and without GvHD with special consideration of the respective area under the ROC (AUROC). The AUROC values illustrate the strength of a discriminating marker, that is, the better a diagnostic marker can discriminate between two conditions, the closer its AUROC value is to 1. The optimal cutoff point for nestin + stem cell niche number for clinically revenant GvHD was calculated using Youden's index (Y)-Y = sensitivity+specificity −1-because this method can be applied to find the optimal cutoff value with the highest sensitivity and specificity when there is no particular requirement for sensitivity and/or specificity. 26 Differences were considered statistically significant at Po0.05; two-sided tests were used throughout the analysis. Abbreviations: allo-HSCT = allogeneic hematopoietic stem cell transplantation; AML = acute myelogenous leukemia; Bu = Busulfan; Cy = Cyclophosphamide; GvHD = graft-versus-host disease; HSCT = allogeneic hematopoietic stem cell transplantation; TBI = total body irradiation; WHO = World Health Organization. siblings (n = 5) or matched unrelated donors (n = 3). In the validation cohort, the donors were matched siblings (n = 23) or matched unrelated donors (n = 17). The median time interval from HSCT to aGvHD onset of any grade was 20 days (range 13-122 days) in both cohorts. The aGvHD type was classic acute in four patients in the test cohort. The aGvHD type was classic acute in 18 patients and late-onset acute in 2 patients in the validation cohort. Acute GvHD resolved in all patients after standard therapy.
RESULTS

Patients
Nestin expression and microvascular density in aGvHD Nestin positively stained the cytoplasms of perivascular cells and clusters representing the HSCN (Figure 1 ). Endothelial cells and scattered BM blasts stained positively for CD34 with moderate-tostrong intensity (Figures 1a-f) . The staining pattern was uniformly cytoplasmic. In all cases studied, CD34 + blasts were o 1%. In the nestin/CD34 double staining, we observed microvessels with surrounding nestin + cells as well as 'CD34-only' staining microvessels without nestin cuffing.
In the validation cohort, we found no significant pretransplant differences in nestin + HSCN between patients with and without aGvHD ( Table 3 ). In patients with aGvHD, nestin + HSCN were reduced at the time point of aGvHD in both the test and validation cohorts (see next paragraph), whereas these niches remained stable 1-4 months post transplant in patients without GvHD (Table 3, Figure 2 and Supplementary Figure S1) .
At the time point of aGvHD, MVD was elevated (18.7 ± 5.9 versus 13.1 ± 6.2 vessels/mm 2 ; P = 0.004; as reported previously) in the test cohort. 13 By contrast, the number of nestin + HSCN was markedly reduced in patients with aGvHD compared with patients without aGvHD (P = 0.04) ( Table 3 ). In the validation cohort, an increased MVD in patients with any aGvHD or clinically relevant aGvHD (P = 0.001 and 0.007, respectively) was observed, whereas the nestin + HSCN number was reduced (P = 0.05 and 0.09, respectively) (Table 3, Figure 2 and Supplementary Figure S1 ). The receiver operating curves and Y suggested a potential discriminatory power of nestin + HSCN quantities for the set variable aGvHD (AUROC = 0.68, 95% confidence interval . Applying this cutoff score, 9/11 (82%) patients with clinically relevant aGvHD (⩾ grade 2) and 13/20 (65%) with any type of GvHD had decreased nestin + HSCN numbers compared with only 10/29 (34%) patients without clinically relevant aGvHD (P = 0.007) and 6/20 (30%) patients without any type of GvHD (P = 0.028).
After aGvHD resolved or (for patients who did not have GvHD) 6-12 months after allo-HSCT, in patients with previous aGvHD the nestin + HSCN numbers increased to the pre-HSCT levels (Table 3 , Figure 2 and Supplementary Figure S1 ), whereas in patients who did not have aGvHD the number of nestin + HSCN remained stable.
FoxP3 and pro-collagen 1 expression We found no significant differences regarding FoxP3 + cells per mm 2 (1.23 ±0.98 versus 0.82 ± 0.76; P = 0.290) and pro-collagen 1 + osteoblasts (data not shown) between patients with and without aGvHD (Supplementary Figure S2) .
Correlation with clinical features Nestin + HSCN quantities did not correlate with any of the known parameters for the whole validation cohort or for the aGvHD subcohort, including sex, age, AML subtype, conditioning regimen, BM cellularity, FoxP3
+ and pro-collagen 1 + osteoblast amounts. Full blood counts were available at the time point of BM biopsy. In patients with clinically relevant aGvHD, we found higher total white blood cell counts (9.3 ± 4.9 versus 5.9 ± 2.9 g/L; P = 0.033) and neutrophil counts (6.7 ± 3.9 versus 3.9 ± 2.5 g/L; P = 0.028) compared with patients without aGvHD. The higher counts were due to the concurrently applied steroid therapy in patients with clinically relevant aGvHD. We found no differences in platelet counts and hemoglobin levels between patients with and without aGvHD. No correlation between blood cell counts and MVD and nestin + clusters was found.
DISCUSSION
The stem cell niche and the formation of new blood vessels appear to be involved in and to be targets of GvHD. 5, 11, 14 We examined the role of nestin + HSCN and angiogenesis in patients with AML with and without aGvHD and found that, despite an increase in BM MVD, the number of nestin + HSCN is markedly reduced in patients with aGvHD compared with patients without aGvHD. After aGvHD resolved, the levels of nestin + HSCN increased to the ranges before allo-HSCT. To the best of our Abbreviations: after aGvHD resolve = time point of biopsy after aGvHD resolve or (for patients who did not suffer from GvHD) 6-12 months after allo-HSCT; aGvHD = acute graft-versus-host disease; allo-HSCT = allogeneic hematopoietic stem cell transplantation; at aGvHD = time point of biopsy at onset of aGvHD or (for patients who did not suffer from GvHD) 1-4 months after allo-HSCT; HSCN = hematopoietic stem cell niches; MVD = microvessel density; pre-HSCT = time point of biopsy directly before allo-HSCT. knowledge, no previous study has examined the correlations of nestin + HSCN, angiogenesis in BM and aGvHD. Suppression of hematopoiesis during aGvHD has long been observed in both clinical and experimental studies, suggesting a stem cell niche malfunction. 27 It has been reported that osteoblasts of the endosteal niche are targets of aGvHD. 5 However, our present results are not suggestive of morphological or quantitative changes in osteoblasts in aGvHD. Whether the perivascular niche is also involved in aGvHD is still debatable. In a study by Yao et al., 14 sinusoidal endothelial cells of the perivascular niche were identified as a target for aGvHD in an MHC-haploidentical murine aGvHD model. These endothelial cells were shown to be destroyed by donor CD4+ T cells. 14 The authors showed that hematopoietic cells were not directly affected by aGvHD, because such cells isolated from GvHD mice exhibited a normal ability to reconstitute hematopoiesis in recipient mice. These results indicate that HSCN impairment is directly linked to hematopoietic impairment in aGvHD. Our present findings agree with and considerably extend these early animal model results, suggesting a role for perivascular nestin + HSCN in patients with aGvHD and, particularly, clinically relevant aGvHD. In the context of adult BM, nestin identifies the perivascular HSCN, whereas CD34 stains mature microvessels in the BM. Because we found increased MVD in aGvHD and decreased nestin + clusters, it seems that, in spite of neoangiogenesis with retained endothelial proliferative activity and differentiation capacity into mature blood vessels, the number of nestin + HSCN is specifically lower in aGvHD. This partly explains the above-mentioned animal model results.
14 Pro-inflammatory signaling by interleukins and interferons has recently been shown to disrupt nestin + HSCN in myeloproliferative neoplasms, 21 and it is tempting to speculate that the changes in signaling cytokines in aGvHD 5 are the underlying mechanism of the reduction in the number of nestin + HSCN during episodes of aGvHD. Importantly, and of direct practical impact, Arranz et al. 21 showed not only that nestin + mesenchymal stem cells were strongly reduced in the BM of patients with myeloproliferative neoplasms (as a result of sympathetic nerve damage and apoptosis of nestin + mesenchymal stem cells triggered by cytokine signaling of the mutant HSCs) but also that these effects are in turn reversible by compensating for the sympathetic neuropathy by treatment with beta-3-sympathocomimetic drugs, correcting the damage to the stem cell niche and leading to a dramatic phenotypic improvement. Whether the use of beta-3 sympathomimetic agonists might represent a novel nicheprotecting therapeutic option bypassing known barriers and limitations related to immunosuppression in aGvHD is still not known. Our data suggest that this approach may merit future clinical evaluation.
In summary, our results indicate that nestin + HSCN and angiogenesis in the BM show reciprocal numerical changes in aGvHD. Whether decreased numbers of nestin + HSCN and increased neovascularization are secondary reactions in response to inflammation or direct GvHD-related processes is currently unknown; however, these characteristics probably represent useful and potentially therapeutically targetable pathways, bypassing pathways related to immunosuppression, and require further clinical studies. 13 
